A Phase 1, Double-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia-Naive Human Immunodeficiency Virus (HIV)-Seropositive Subjects
Phase of Trial: Phase I/II
Latest Information Update: 21 Jan 2014
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 31 Aug 2018 Biomarkers information updated
- 06 Jan 2009 Planned number of patients changed from 405 to 2 as reported by ClinicalTrials.gov.
- 06 Jan 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.